Literature DB >> 10545015

Ras gene activation in malignant cells of human ovarian carcinoma peritoneal fluids.

D N Dokianakis1, M N Varras, M Papaefthimiou, J Apostolopoulou, H Simiakaki, E Diakomanolis, D A Spandidos.   

Abstract

In this study, we showed, for the first time, the pattern of point mutations at codon 12 of the K-ras, H-ras and N-ras genes, using polymerase chain reaction and restriction fragment length polymorphism analysis in 47 malignant cytologic specimens of ovarian adenocarcinoma peritoneal fluids. Forty-seven % of the samples were found to carry a point mutation at codon 12 of K-ras gene. Also, 21 cystadenoma peritoneal fluids were used as control specimens for the detection of ras mutations. Fourteen % of these samples were found to carry a point mutation at codon 12 of the K-ras gene. The prevalence of K-ras gene mutations were statistically correlated with FIGO and surgical stage of the malignant specimens. Our data demonstrates that the K-ras gene mutations are mainly affected (47%) in the malignant cells of the peritoneal washings or ascites of women with ovarian adenocarcinomas and may have value for the early diagnosis and monitoring of these neoplasms.

Entities:  

Mesh:

Year:  1999        PMID: 10545015     DOI: 10.1023/a:1006611220434

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  18 in total

1.  Detection of HPV and ras gene mutations in cervical smears from female genital lesions.

Authors:  D N Dokianakis; G Sourvinos; S Sakkas; E Athanasiadou; D A Spandidos
Journal:  Oncol Rep       Date:  1998 Sep-Oct       Impact factor: 3.906

2.  Mutational activation of k-ras oncogene in human breast-tumors.

Authors:  M Koffa; V Malamoumitsi; N Agnantis; D Spandidos
Journal:  Int J Oncol       Date:  1994-03       Impact factor: 5.650

3.  c-K-ras mutations in human carcinomas occur preferentially in codon 12.

Authors:  L Yanez; J Groffen; D M Valenzuela
Journal:  Oncogene       Date:  1987       Impact factor: 9.867

4.  ras gene mutations in human endometrial carcinoma.

Authors:  M N Varras; M Koffa; E Koumantakis; M Ergazaki; E Protopapa; S Michalas; D A Spandidos
Journal:  Oncology       Date:  1996 Nov-Dec       Impact factor: 2.935

5.  K-ras oncogene mutations in neoplasias of kidney transplanted patients: preliminary results with a new technique.

Authors:  G D Skalkeas; D A Spandidos; A Kostakis; S Balafouta-Tseleni; E Choremi; D Iliopoulos; A Haliassos
Journal:  Anticancer Res       Date:  1991 Nov-Dec       Impact factor: 2.480

Review 6.  The role of p21ras in receptor tyrosine kinase signalling.

Authors:  G J Pronk; J L Bos
Journal:  Biochim Biophys Acta       Date:  1994-12-30

Review 7.  Ovarian intraepithelial neoplasia and ovarian cancer.

Authors:  D M Gershenson; G Tortolero-Luna; A Malpica; V V Baker; L Whittaker; E Johnson; M Follen Mitchell
Journal:  Obstet Gynecol Clin North Am       Date:  1996-06       Impact factor: 2.844

8.  Flow cytometric evaluation of epithelial ovarian cancer.

Authors:  V M Barnabei; D S Miller; K D Bauer; T M Murad; A W Rademaker; J R Lurain
Journal:  Am J Obstet Gynecol       Date:  1990-06       Impact factor: 8.661

9.  The application of flow cytometric DNA analysis in detecting the presence of malignant cells in ovarian carcinoma peritoneal fluids.

Authors:  S Kehoe; K Ward; D Luesley; K K Chan
Journal:  Br J Obstet Gynaecol       Date:  1995-08

10.  Activated ras genes in human seminoma: evidence for tumor heterogeneity.

Authors:  M P Mulder; W Keijzer; A Verkerk; A J Boot; M E Prins; T A Splinter; J L Bos
Journal:  Oncogene       Date:  1989-11       Impact factor: 9.867

View more
  5 in total

1.  Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.

Authors:  Daniela Matei; Michael W Sill; Heather A Lankes; Koen DeGeest; Robert E Bristow; David Mutch; S Diane Yamada; David Cohn; Valerie Calvert; John Farley; Emanuel F Petricoin; Michael J Birrer
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

2.  Oncolytic virotherapy for ovarian cancer.

Authors:  Shoudong Li; Jessica Tong; Masmudur M Rahman; Trevor G Shepherd; Grant McFadden
Journal:  Oncolytic Virother       Date:  2012-08

3.  Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.

Authors:  Deyin Xing; Yohan Suryo Rahmanto; Felix Zeppernick; Charlotte G Hannibal; Susanne K Kjaer; Russell Vang; Ie-Ming Shih; Tian-Li Wang
Journal:  Hum Pathol       Date:  2017-09-02       Impact factor: 3.466

4.  Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.

Authors:  Sandra Orsulic; Yi Li; Robert A Soslow; Lynn A Vitale-Cross; J Silvio Gutkind; Harold E Varmus
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

5.  Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients.

Authors:  Marci E Schaner; Ben Davidson; Martina Skrede; Reuven Reich; Vivi Ann Flørenes; Björn Risberg; Aasmund Berner; Iris Goldberg; Vered Givant-Horwitz; Claes G Tropè; Gunnar B Kristensen; Jahn M Nesland; Anne-Lise Børresen-Dale
Journal:  Mol Cancer       Date:  2005-07-21       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.